Patents by Inventor Misaki Homma
Misaki Homma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11746109Abstract: The present disclosure relates to crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate (Compound 1) and/or tautomers thereof, wherein Compound 1 has the structure: (I)ยท0.5H2O; processes for preparing crystalline forms of Compound 1 and/or tautomers thereof; pharmaceutical compositions comprising the crystalline forms; methods of inhibiting a cell division cycle 7 in a mammal comprising administering the crystalline forms; and methods of treating a cell division cycle 7 mediated cancer in a mammal comprising administering the crystalline forms or a pharmaceutical composition comprising the crystalline forms.Type: GrantFiled: March 27, 2017Date of Patent: September 5, 2023Assignee: Takeda Pharmaceutical Company LimitedInventors: Kentaro Iwata, Masahiro Mizuno, Kazuhiro Maeda, Tsuneo Yasuma, Misaki Homma, Yuya Oguro, Naohiro Taya, Lei Zhu, John Daniel Bailey, Marianne Langston, Siddhesh Dinanath Patil, Shruti Gour, Lilly Roy
-
Publication number: 20230102273Abstract: The present disclosure relates to crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate (Compound 1) and/or tautomers thereof, wherein Compound 1 has the structure: (I).0.5H2O; processes for preparing crystalline forms of Compound 1 and/or tautomers thereof; pharmaceutical compositions comprising the crystalline forms; methods of inhibiting a cell division cycle 7 in a mammal comprising administering the crystalline forms; and methods of treating a cell division cycle 7 mediated cancer in a mammal comprising administering the crystalline forms or a pharmaceutical composition comprising the crystalline forms.Type: ApplicationFiled: March 27, 2017Publication date: March 30, 2023Inventors: Kentaro IWATA, Masahiro MIZUNO, Kazuhiro MAEDA, Tsuneo YASUMA, Misaki HOMMA, Yuya OGURO, Naohiro TAYA, Lei ZHU, John Daniel BAILEY, Marianne LANGSTON, Siddhesh Dinanath PATIL, Shruti GOUR, Lilly ROY
-
Publication number: 20220098180Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.Type: ApplicationFiled: January 29, 2020Publication date: March 31, 2022Applicant: Takeda Pharmaceutical Company LimitedInventors: Masahiro ITO, Takeshi YAMAMOTO, Keiko KAKEGAWA, Hideyuki SUGIYAMA, Tohru MIYAZAKI, Yasuyoshi ARIKAWA, Tomohiro OKAWA, Jinichi YONEMORI, Osamu KUBO, Akinori TOITA, Takuto KOJIMA, Fumiaki KIKUCHI, Minoru SASAKI, Misaki HOMMA, Yasuhiro IMAEDA, Hironobu MAEZAKI, Shiinobu SASAKI, Ayumu SATO, Hirotaka KAMITANI, Yasutomi ASANO, Hironori KOKUBO, Masato YOSHIKAWA
-
Patent number: 10435399Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: July 30, 2018Date of Patent: October 8, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Masahiro Ito, Hideyuki Sugiyama, Osamu Kubo, Fumiaki Kikuchi, Takeshi Yasui, Keiko Kakegawa, Zenichi Ikeda, Tohru Miyazaki, Yasuyoshi Arikawa, Tomohiro Okawa, Jinichi Yonemori, Akinori Toita, Takuto Kojima, Yasutomi Asano, Ayumu Sato, Hironobu Maezaki, Shinobu Sasaki, Hironori Kokubo, Misaki Homma, Minoru Sasaki, Yasuhiro Imaeda
-
Publication number: 20190135799Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: July 30, 2018Publication date: May 9, 2019Inventors: Masahiro ITO, Hideyuki SUGIYAMA, Osamu KUBO, Fumiaki KIKUCHI, Takeshi YASUI, Keiko KAKEGAWA, Zenichi IKEDA, Tohru MIYAZAKI, Yasuyoshi ARIKAWA, Tomohiro OKAWA, Jinichi YONEMORI, Akinori TOITA, Takuto KOJIMA, Yasutomi ASANO, Ayumu SATO, Hironobu MAEZAKI, Shinobu SASAKI, Hironori KOKUBO, Misaki HOMMA, Minoru SASAKI, Yasuhiro IMAEDA
-
Publication number: 20170209452Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: ApplicationFiled: April 11, 2017Publication date: July 27, 2017Inventors: Misaki HOMMA, Toru MIYAZAKI, Yuya OGURO, Osamu KURASAWA
-
Patent number: 9655900Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: GrantFiled: June 8, 2016Date of Patent: May 23, 2017Assignee: Takeda Pharmaceutical Company LimitedInventors: Misaki Homma, Toru Miyazaki, Yuya Oguro, Osamu Kurasawa
-
Publication number: 20160310494Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: ApplicationFiled: June 8, 2016Publication date: October 27, 2016Inventors: Misaki HOMMA, Toru MIYAZAKI, Yuya OGURO, Osamu KURASAWA
-
Patent number: 9388195Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: GrantFiled: December 10, 2014Date of Patent: July 12, 2016Assignee: Takeda Pharmaceutical Company LimitedInventors: Misaki Homma, Toru Miyazaki, Yuya Oguro, Osamu Kurasawa
-
Publication number: 20150158882Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: ApplicationFiled: December 10, 2014Publication date: June 11, 2015Inventors: Misaki HOMMA, Toru MIYAZAKI, Yuya OGURO, Osamu KURASAWA
-
Patent number: 8933069Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: GrantFiled: March 24, 2014Date of Patent: January 13, 2015Assignee: Takeda Pharmaceutical Company LimitedInventors: Misaki Homma, Yuya Oguro
-
Patent number: 8921354Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: GrantFiled: March 24, 2014Date of Patent: December 30, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Misaki Homma, Toru Miyazaki
-
Publication number: 20140235615Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: ApplicationFiled: March 24, 2014Publication date: August 21, 2014Applicant: Takeda Pharmaceutical Company LimitedInventors: Misaki HOMMA, Toru MIYAZAKI, Yuya OGURO, Osamu KURASAWA
-
Publication number: 20140228352Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: ApplicationFiled: March 24, 2014Publication date: August 14, 2014Applicant: Takeda Pharmaceutical Company LimitedInventors: Misaki HOMMA, Toru MIYAZAKI, Yuya OGURO, Osamu KURASAWA
-
Patent number: 8722660Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: GrantFiled: February 16, 2011Date of Patent: May 13, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Misaki Homma, Toru Miyazaki
-
Publication number: 20130029969Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: ApplicationFiled: February 16, 2011Publication date: January 31, 2013Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Misaki Homma, Toru Miyazaki, Yuya Oguro, Osamu Kurasawa